DRMA Dermata Therapeutics, Inc.: institutional ownership and insider trading
13 funds reported holding $158K of Dermata Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $20.7K, with 7 new positions and 1 funds selling out; over the last 12 months insiders bought $1.27K and sold $13 on the open market.
Largest institutional holders of DRMA
- GEODE CAPITAL MANAGEMENT, LLC — $26.1K
- WELCH & FORBES LLC — $25.8K
- STATE STREET CORP (STT, STT-PG) — $24.2K
- UBS Group AG (UBS) — $21.7K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $20.6K
- XTX Topco Ltd — $19.1K
- Advisory Alpha, LLC — $12.9K
- Tower Research Capital LLC (TRC) — $4.98K
- MCF Advisors LLC — $2.24K
- BARCLAYS PLC (BCS, BCLYF) — $348
Recent DRMA insider trades
- Jun 16, 2026: Scott Kathleen D. sold 11 shares ($13)
- Feb 17, 2026: Bedoya-Toro Munera Maria E bought 1,000 shares ($1.27K)
5%+ owners
- Kyri K. Van Hoose: 9.0% (Schedule 13D, filed Jun 1, 2026)